Study summary · research use only
Vitiligo: Pathogenesis and New and Emerging Treatments
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review article (species not specified; qualitative literature review of 116 articles) discusses the pathogenesis of vitiligo and available and emerging treatments. The authors describe reviewing the mechanism of action and reported outcomes of phototherapy, afamelanotide, cyclosporine, phosphodiesterase 4 inhibitors, trichloroacetic acid, basic fibroblast growth factor, TNF inhibitors, secukinumab, pseudocatalase, and JAK inhibitors. The authors state that no clearly outstanding or fully satisfactory treatment for vitiligo currently exists, and describe a continued need for new drug development along with longer-term outcome data for existing treatments.
Abstract
Vitiligo is a complex disease with a multifactorial nature and a high impact on the quality of life of patients. Although there are multiple therapeutic alternatives, there is currently no fully effective treatment for this disease. In the current era, multiple drugs are being developed for the treatment of autoimmune diseases. This review assesses the available evidence on the pathogenesis of vitiligo, and a comprehensive review of treatments available for vitiligo now and in the near future is provided. This qualitative analysis spans 116 articles. We reviewed the mechanism of action, efficacy and safety data of phototherapy, afamelanotide, cyclosporine, phosphodiesterase 4 inhibitors, trichloroacetic acid, basic fibroblast growth factor, tumor necrosis factor (TNF) inhibitors, secukinumab, pseudocatalase and janus kinase (JAK) inhibitors. At the moment, there is no clearly outstanding option or fully satisfactory treatment for vitiligo, so it is necessary to keep up the development of new drugs as well as the publication of long-term effectiveness and safety data for existing treatments.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.